Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Cirrhosis

Free Subscription Articles published in J Gastroenterol Hepatol Retrieve available abstracts of 92 articles: HTML format

Single Articles

October 2025
1. KIM MN, Park GU, You SC, Lee JS, et al
   Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.
   J Gastroenterol Hepatol. 2025 Oct 1. doi: 10.1111/jgh.70078.
   PubMed     Abstract available
   
   
   
2. SHI H, Dou D, Zhang F, Du Y, et al
   Prevalence and Bidirectional Association Between Autoimmune Liver Disease and Inflammatory Bowel Disease: A Meta-Analysis.
   J Gastroenterol Hepatol. 2025;40:2362-2372.
   PubMed     Abstract available
   
   
   
3. ZENG X, Li Z, Chen Y, Yao H, et al
   Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
   J Gastroenterol Hepatol. 2025;40:2601-2612.
   PubMed     Abstract available
   
   
   August 2025
4. HEGAZY RA
   Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics.
   J Gastroenterol Hepatol. 2025 Aug 3. doi: 10.1111/jgh.70037.
   PubMed     Abstract available
   
   
   July 2025
5. CHEN Y, Zhai D, Shen J, Hu W, et al
   Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
   J Gastroenterol Hepatol. 2025 Jul 26. doi: 10.1111/jgh.70003.
   PubMed     Abstract available
   
   
   
6. JANG TY, Wang CW, Liang PC, Wei YJ, et al
   Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis B.
   J Gastroenterol Hepatol. 2025 Jul 24. doi: 10.1111/jgh.70021.
   PubMed     Abstract available
   
   
   June 2025
7. CAINES A, Lu M, Wu T, Trudeau S, et al
   Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis.
   J Gastroenterol Hepatol. 2025 Jun 23. doi: 10.1111/jgh.17035.
   PubMed     Abstract available
   
   
   
8. WANG L, Zhao Y, Duan B, Wang Y, et al
   Iron Quantification Using Spectral CT-Based Material Decomposition Technique for Noninvasive Hepatic Fibrosis Staging: An Experimental Study.
   J Gastroenterol Hepatol. 2025 Jun 4. doi: 10.1111/jgh.17031.
   PubMed     Abstract available
   
   
   
9. XIA Y, Tie J, Wang G, Wu H, et al
   Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or Refractory ascites: A Multicenter Cohort Study.
   J Gastroenterol Hepatol. 2025;40:1574-1585.
   PubMed     Abstract available
   
   
   May 2025
10. MATSUBARA Y, Tsuboi A, Shigenobu S, Hirata I, et al
    Clinical Significance of Small-Bowel Mucosal Changes in Liver Cirrhosis Patients With Suspected Small-Bowel Bleeding: A Capsule Endoscopy Study.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.17002.
    PubMed     Abstract available
    
    
    
11. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.16999.
    PubMed     Abstract available
    
    
    April 2025
12. TAMAKI N, Huang DQ, Lee HW, Park SY, et al
    Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.
    J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16986.
    PubMed     Abstract available
    
    
    
13. OGAWA E, Kawano A, Kohjima M, Koyanagi T, et al
    Long-Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct-Acting Antivirals.
    J Gastroenterol Hepatol. 2025;40:971-978.
    PubMed     Abstract available
    
    
    March 2025
14. 
    Correction to 'Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance'.
    J Gastroenterol Hepatol. 2025 Mar 14. doi: 10.1111/jgh.16918.
    PubMed    
    
    
    
15. JAFARI-KHORCHANI M, Pantopoulos K, Zare-Mehrjardi MJ, Allameh A, et al
    Sequential Changes in NOX4 Expression, Oxidative Stress Indices, PIIINP, and Liver Histopathology During Hepatocellular Carcinogenesis Induced in Mice.
    J Gastroenterol Hepatol. 2025 Mar 3. doi: 10.1111/jgh.16914.
    PubMed     Abstract available
    
    
    
16. JIANG H, Yu H, Huang Y, Li M, et al
    Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase.
    J Gastroenterol Hepatol. 2025;40:720-730.
    PubMed     Abstract available
    
    
    
17. JAYABALAN D, Huang Y, Calzadilla-Bertot L, Adams LA, et al
    Natural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study.
    J Gastroenterol Hepatol. 2025;40:731-740.
    PubMed     Abstract available
    
    
    February 2025
18. GIRI S, Ingawale S, Khatana G, Gore P, et al
    Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021.
    J Gastroenterol Hepatol. 2025 Feb 27. doi: 10.1111/jgh.16922.
    PubMed     Abstract available
    
    
    
19. NAKAKUKI N, Maekawa S, Takano S, Osawa L, et al
    TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next-Generation Sequencing.
    J Gastroenterol Hepatol. 2025;40:537-547.
    PubMed     Abstract available
    
    
    January 2025
20. PENG J, Zhang L, Dong Y, Long W, et al
    Factors Influencing Liver Cirrhosis Progression in Wilson's Disease Patients: A Retrospective Cohort Study Over 5 Years.
    J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16889.
    PubMed     Abstract available
    
    
    
21. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Validation of serum non-invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia.
    J Gastroenterol Hepatol. 2025;40:241-249.
    PubMed     Abstract available
    
    
    December 2024
22. MALANDRIS K, Arampidis D, Mainou M, Papadopoulos N, et al
    FibroScan-AST score for diagnosing fibrotic MASH: A systematic review and meta-analysis of diagnostic test accuracy studies.
    J Gastroenterol Hepatol. 2024;39:2582-2591.
    PubMed     Abstract available
    
    
    
23. PAN L, Wang L, Ma H, Ding F, et al
    Relevance of combined influence of nutritional and inflammatory status on non-alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of lipid biomarkers.
    J Gastroenterol Hepatol. 2024;39:2853-2862.
    PubMed     Abstract available
    
    
    
24. KIM K, Lee Y, Lee JS, Kim MN, et al
    Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    J Gastroenterol Hepatol. 2024;39:2845-2852.
    PubMed     Abstract available
    
    
    
25. CHANG ML, Le PH, Chen WT, Chen TD, et al
    Distinct characteristics of various autoimmune liver diseases: A 22-year hospital-based study in Taiwan.
    J Gastroenterol Hepatol. 2024;39:2835-2844.
    PubMed     Abstract available
    
    
    
26. MAK LY, Hui RW, Chung MSH, Wong DK, et al
    Regression of liver fibrosis after HBsAg loss: A prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test.
    J Gastroenterol Hepatol. 2024;39:2826-2834.
    PubMed     Abstract available
    
    
    November 2024
27. JAROENLAPNOPPARAT A, Prasitsumrit V, Ponvilawan B, Waitayangkoon P, et al
    Clostridioides difficile infection increases in-hospital mortality, length of stay, and hospital cost but not 30-day mortality in cirrhotic patients.
    J Gastroenterol Hepatol. 2024 Nov 13. doi: 10.1111/jgh.16807.
    PubMed     Abstract available
    
    
    
28. ZENG X, Liao Y, Cheng W
    Transient receptor potential channel 6 knockout ameliorates hepatic fibrosis by inhibiting the activation and proliferation of hepatic stellate cells.
    J Gastroenterol Hepatol. 2024 Nov 7. doi: 10.1111/jgh.16802.
    PubMed     Abstract available
    
    
    
29. CHANG YP, Liu CH, Huang CB, Lee JY, et al
    Serum Mac-2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus.
    J Gastroenterol Hepatol. 2024;39:2439-2446.
    PubMed     Abstract available
    
    
    
30. WONGTRAKUL W, Niltwat S, Charatcharoenwitthaya N, Karaketklang K, et al
    Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2299-2307.
    PubMed     Abstract available
    
    
    October 2024
31. PRINCE DS, Hoque S, Kim C, Maher S, et al
    Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance.
    J Gastroenterol Hepatol. 2024 Oct 24. doi: 10.1111/jgh.16782.
    PubMed     Abstract available
    
    
    
32. LI Y, Chen L, Li S, Song H, et al
    The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization.
    J Gastroenterol Hepatol. 2024 Oct 15. doi: 10.1111/jgh.16765.
    PubMed     Abstract available
    
    
    
33. LEOW YW, Chan WL, Lai LL, Mustapha NRN, et al
    LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:2182-2189.
    PubMed     Abstract available
    
    
    
34. YU H, Huang Y, Li M, Jiang H, et al
    Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease.
    J Gastroenterol Hepatol. 2024;39:2169-2181.
    PubMed     Abstract available
    
    
    
35. YANG J, Choi WM, Lee D, Shim JH, et al
    Revisiting the steatosis-associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability.
    J Gastroenterol Hepatol. 2024;39:2112-2119.
    PubMed     Abstract available
    
    
    
36. ALATAS FS, Yamaza T, Matsuura T, Ongko L, et al
    Potential role of stem cells from human exfoliated deciduous teeth in inducing liver regeneration.
    J Gastroenterol Hepatol. 2024;39:2190-2196.
    PubMed     Abstract available
    
    
    September 2024
37. PASSOS PRC, Filho VOC, Noronha MM, Hyppolito EB, et al
    Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Sep 25. doi: 10.1111/jgh.16752.
    PubMed     Abstract available
    
    
    August 2024
38. BANERJEE A, Blinston D, Narain MA
    Inhibition of liver fibrosis by TET1 may be B cell mediated: Supporting evidence from a case of TNFAIP3 deficiency.
    J Gastroenterol Hepatol. 2024;39:1706-1707.
    PubMed    
    
    
    July 2024
39. MALANDRIS K, Papandreou S, Vasilakou D, Kakotrichi P, et al
    Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.
    J Gastroenterol Hepatol. 2024;39:1219-1229.
    PubMed     Abstract available
    
    
    June 2024
40. MALIK S, Tenorio BG, Moond V, Dahiya DS, et al
    Systematic review of machine learning models in predicting the risk of bleed/grade of esophageal varices in patients with liver cirrhosis: A comprehensive methodological analysis.
    J Gastroenterol Hepatol. 2024 Jun 17. doi: 10.1111/jgh.16645.
    PubMed     Abstract available
    
    
    
41. WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al
    LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites.
    J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637.
    PubMed     Abstract available
    
    
    
42. LEE JS, Lee HW, Kim MN, Kim BK, et al
    Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center.
    J Gastroenterol Hepatol. 2024;39:1155-1163.
    PubMed     Abstract available
    
    
    May 2024
43. HAYASHI M, Abe K, Sugaya T, Takahata Y, et al
    A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 May 30. doi: 10.1111/jgh.16639.
    PubMed     Abstract available
    
    
    
44. SUN Z, Guo Y, Xu X, Zhou C, et al
    Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway.
    J Gastroenterol Hepatol. 2024 May 28. doi: 10.1111/jgh.16635.
    PubMed     Abstract available
    
    
    
45. LIM J, Kim JH, Kim SE, Han SK, et al
    Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort.
    J Gastroenterol Hepatol. 2024 May 8. doi: 10.1111/jgh.16591.
    PubMed     Abstract available
    
    
    
46. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    PubMed     Abstract available
    
    
    
47. LEE S, Choi J, Park JH, Lim CY, et al
    Dynamic liver volume change in predicting hepatic decompensation and long-term effects of stereotactic body radiation therapy.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588.
    PubMed     Abstract available
    
    
    
48. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    PubMed     Abstract available
    
    
    April 2024
49. LIU Y, Hu Y, Li B, Su R, et al
    Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 Apr 12. doi: 10.1111/jgh.16547.
    PubMed     Abstract available
    
    
    March 2024
50. WANG X, Liu H, Wang Y, Wang P, et al
    Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
    J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
    PubMed     Abstract available
    
    
    February 2024
51. 
    Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
    PubMed    
    
    
    
52. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    PubMed     Abstract available
    
    
    January 2024
53. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    PubMed     Abstract available
    
    
    
54. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    PubMed     Abstract available
    
    
    
55. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    PubMed     Abstract available
    
    
    December 2023
56. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    PubMed    
    
    
    November 2023
57. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    PubMed     Abstract available
    
    
    
58. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    PubMed    
    
    
    October 2023
59. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    PubMed     Abstract available
    
    
    
60. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    PubMed    
    
    
    
61. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    PubMed     Abstract available
    
    
    
62. SHAHRANI S, Gill SS, Sooi CY, Skantha R, et al
    Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease.
    J Gastroenterol Hepatol. 2023;38:1818-1822.
    PubMed     Abstract available
    
    
    September 2023
63. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    PubMed     Abstract available
    
    
    
64. GASPAR R, Silva M, Cardoso P, Goncalves R, et al
    Spleen stiffness: a new tool to predict high-risk varices in cirrhotic patients.
    J Gastroenterol Hepatol. 2023 Sep 1. doi: 10.1111/jgh.16344.
    PubMed     Abstract available
    
    
    August 2023
65. JIANG H, Xu N, Zhang W, Wei H, et al
    Do gut microbiome-targeted therapies improve liver function in cirrhotic patients? A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023 Aug 15. doi: 10.1111/jgh.16329.
    PubMed     Abstract available
    
    
    
66. ANIRVAN P
    Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Aug 12. doi: 10.1111/jgh.16328.
    PubMed    
    
    
    
67. LI R, Liu J, Han P, Shi R, et al
    Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index.
    J Gastroenterol Hepatol. 2023;38:1316-1324.
    PubMed     Abstract available
    
    
    
68. CHETWOOD JD, Sabih AH, Chan K, Salimi S, et al
    Epidemiology, characteristics, and outcomes of patients with acute-on-chronic liver failure in Australia.
    J Gastroenterol Hepatol. 2023;38:1325-1332.
    PubMed     Abstract available
    
    
    July 2023
69. CHO MS, Lee SK, Kwon JH, Nam SW, et al
    Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis.
    J Gastroenterol Hepatol. 2023 Jul 10. doi: 10.1111/jgh.16277.
    PubMed    
    
    
    
70. CHOI WM, Yoo SY, Chang JI, Han S, et al
    A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization.
    J Gastroenterol Hepatol. 2023 Jul 7. doi: 10.1111/jgh.16280.
    PubMed     Abstract available
    
    
    
71. PODDAR U, Samanta A, Sarma MS, Kumar B, et al
    How to suspect the presence of high-risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
    J Gastroenterol Hepatol. 2023 Jul 5. doi: 10.1111/jgh.16267.
    PubMed     Abstract available
    
    
    
72. LIU M, Qiu H, Zhang W, Mei T, et al
    Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1018-1027.
    PubMed     Abstract available
    
    
    
73. SHEN J, Cao J, Chen M, Zhang Y, et al
    Recent advances in the role of exosomes in liver fibrosis.
    J Gastroenterol Hepatol. 2023;38:1083-1088.
    PubMed     Abstract available
    
    
    
74. SEDAROUS M, Youssef M, Adekunle AD, Babajide O, et al
    A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States.
    J Gastroenterol Hepatol. 2023;38:1148-1157.
    PubMed     Abstract available
    
    
    
75. JIANG N, Xiao Y, Yuan K, Wang Z, et al
    Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
    J Gastroenterol Hepatol. 2023;38:1056-1071.
    PubMed     Abstract available
    
    
    June 2023
76. MINORETTI P, Emanuele E
    Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16273.
    PubMed    
    
    
    
77. SHARMA BC, Maharshi S, Sachdeva S, Mahajan B, et al
    Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16266.
    PubMed     Abstract available
    
    
    
78. GIRI S, Singh A, Kolhe K, Kale A, et al
    Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16263.
    PubMed     Abstract available
    
    
    
79. ISHIBA H, Sumida Y, Kamada Y, Fujii H, et al
    Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
    J Gastroenterol Hepatol. 2023;38:896-904.
    PubMed     Abstract available
    
    
    May 2023
80. DONG Y, Liu Y, Liu X, Ma H, et al
    Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures.
    J Gastroenterol Hepatol. 2023 May 24. doi: 10.1111/jgh.16221.
    PubMed     Abstract available
    
    
    
81. WU CW, Wong GL, Wong VW, Yam TF, et al
    Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.
    J Gastroenterol Hepatol. 2023 May 22. doi: 10.1111/jgh.16218.
    PubMed     Abstract available
    
    
    
82. KIM DS, Kim BK, Lee JS, Lee HW, et al
    Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis.
    J Gastroenterol Hepatol. 2023 May 15. doi: 10.1111/jgh.16210.
    PubMed     Abstract available
    
    
    
83. TIWARI A, Mehrotra M, Hasan A, Agarwal J, et al
    Hepatitis B virus liver decompensation: antiviral therapy for all.
    J Gastroenterol Hepatol. 2023;38:833-834.
    PubMed    
    
    
    
84. AHMED Z, Badal J, Nawras M, Battepati D, et al
    Role of rifaximin in the management of alcohol-associated hepatitis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:703-709.
    PubMed     Abstract available
    
    
    April 2023
85. VERMA N, Vojjala N, Mishra S, Valsan A, et al
    Machine learning can guide suitability of consultation and patient referral through telemedicine for hepatobiliary diseases.
    J Gastroenterol Hepatol. 2023 Apr 28. doi: 10.1111/jgh.16194.
    PubMed     Abstract available
    
    
    March 2023
86. MNATZAGANIAN G, MacLachlan JH, Allard N, Brown C, et al
    Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16162.
    PubMed     Abstract available
    
    
    
87. WONG GL
    Editorial: Appraising liver fibrosis with eagle eyes.
    J Gastroenterol Hepatol. 2023;38:343.
    PubMed    
    
    
    
88. ZHAO Q, Liang L, Zhai F, Ling G, et al
    A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022.
    J Gastroenterol Hepatol. 2023;38:359-369.
    PubMed     Abstract available
    
    
    February 2023
89. ZHAO X, Shi X, Gu H, Zhou W, et al
    Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: evidence from the NHANES database of the US.
    J Gastroenterol Hepatol. 2023 Feb 18. doi: 10.1111/jgh.16150.
    PubMed     Abstract available
    
    
    January 2023
90. CHO SH, Song TJ, Park JS, Yoon JH, et al
    Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: a multicenter cohort study.
    J Gastroenterol Hepatol. 2023 Jan 29. doi: 10.1111/jgh.16136.
    PubMed     Abstract available
    
    
    
91. BHATEJA A, Bodh V, Chauhan A
    Role of Nutrition in the management of hepatic encephalopathy - Do we know all?
    J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16131.
    PubMed     Abstract available
    
    
    
92. ZHANG Q, Jia R, Chen M, Wang J, et al
    Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and HSCs.
    J Gastroenterol Hepatol. 2023 Jan 18. doi: 10.1111/jgh.16126.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.